View in EDS HTML Full Text PDF Full Text

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.

Saved in:
Bibliographic Details
Title: Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
Authors: Files DC; Department of Internal Medicine, Pulmonary, Critical Care, Allergy and Immunology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America., Tacke F; Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany., O'Sullivan A; AbbVie Inc., North Chicago, Illinois, United States of America., Dorr P; AbbVie Inc., North Chicago, Illinois, United States of America., Ferguson WG; AbbVie Inc., North Chicago, Illinois, United States of America., Powderly WG; John T. Milliken Department of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine in St Louis, St Louis, Missouri, United States of America.
Source: PLoS pathogens [PLoS Pathog] 2022 Jun 24; Vol. 18 (6), pp. e1010547. Date of Electronic Publication: 2022 Jun 24 (Print Publication: 2022).
Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35749425
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Files+DC%22">Files DC</searchLink>; Department of Internal Medicine, Pulmonary, Critical Care, Allergy and Immunology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Tacke+F%22">Tacke F</searchLink>; Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22O'Sullivan+A%22">O'Sullivan A</searchLink>; AbbVie Inc., North Chicago, Illinois, United States of America.<br /><searchLink fieldCode="AU" term="%22Dorr+P%22">Dorr P</searchLink>; AbbVie Inc., North Chicago, Illinois, United States of America.<br /><searchLink fieldCode="AU" term="%22Ferguson+WG%22">Ferguson WG</searchLink>; AbbVie Inc., North Chicago, Illinois, United States of America.<br /><searchLink fieldCode="AU" term="%22Powderly+WG%22">Powderly WG</searchLink>; John T. Milliken Department of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine in St Louis, St Louis, Missouri, United States of America.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101238921%22">PLoS pathogens</searchLink> [PLoS Pathog] 2022 Jun 24; Vol. 18 (6), pp. e1010547. <i>Date of Electronic Publication: </i>2022 Jun 24 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101238921 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1553-7374 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215537366%22">15537366 </searchLink><i>NLM ISO Abbreviation: </i>PLoS Pathog <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35749425
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1371/journal.ppat.1010547
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e1010547
    Titles:
      – TitleFull: Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Files DC
      – PersonEntity:
          Name:
            NameFull: Tacke F
      – PersonEntity:
          Name:
            NameFull: O'Sullivan A
      – PersonEntity:
          Name:
            NameFull: Dorr P
      – PersonEntity:
          Name:
            NameFull: Ferguson WG
      – PersonEntity:
          Name:
            NameFull: Powderly WG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 06
              Text: 2022 Jun 24
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1553-7374
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: PLoS pathogens
              Type: main
ResultId 1